triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC#966103ClinicalTrials.gov
• Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative#158196ClinicalTrials.gov
• Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors#893225ClinicalTrials.gov
• Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy#121370ClinicalTrials.gov
• Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)#903229ClinicalTrials.gov
• A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer#879164ClinicalTrials.gov
• Subtype-Divergent Engagement of Aging-Associated Polycomb Programs in Breast Cancer TWAS Identifies Transcriptional and Lysosomal Vulnerabilities#344078Figshare
• Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease#633737ClinicalTrials.gov
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)#914637ClinicalTrials.gov
• HIF-1–regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer#241038The Learning Edge
• Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple-Negative Breast Cancer.#265577NCBI PubMed Central
• Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes.#781405NCBI PubMed Central
• Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations#806928ClinicalTrials.gov
• PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC#899095ClinicalTrials.gov
• Spatial immune biomarkers in triple-negative breast cancer: emerging evidence, technology trade-offs, and barriers to clinical translation.#975714NCBI PubMed Central
• Study of XB010 in Subjects With Solid Tumors#898289ClinicalTrials.gov
• A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands#208441ClinicalTrials.gov
• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer#857187ClinicalTrials.gov
• A Biomarker Screening Protocol for Participants With Solid Tumors#184830ClinicalTrials.gov
• Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy#307439ClinicalTrials.gov
• Unveiling Gloriosine as a Dual-Acting Regulator of Glutamine Metabolism and Ferroptosis in Triple-Negative Breast Cancer: Insights from Network Pharmacology and Experimental Validation#480169bioRxiv / medRxiv
• Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors#874390ClinicalTrials.gov
• Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature#838788ClinicalTrials.gov
• The role of circular RNAs as miRNA sponges in the mechanisms and therapeutic potential of triple negative breast cancer.#150318NCBI PubMed Central
• Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses#159603Unpaywall
• HIF-1–regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer#261816Europe PMC
• Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer#471828HAL (France)
• OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease#812322ClinicalTrials.gov
• PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC#835671ClinicalTrials.gov
• Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures#890347ClinicalTrials.gov
• A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors#917540ClinicalTrials.gov
• Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer#876680ClinicalTrials.gov
• A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.#854545ClinicalTrials.gov
• Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study#833790ClinicalTrials.gov
• A multiparametric magnetic resonance imaging model incorporating the relative apparent diffusion coefficient for preoperative discrimination of triple-negative breast cancer.#30586NCBI PubMed Central
• Targeting DNA Polymerase Epsilon Induces Tumor Clearance and Activates an NF-κB-Mediated Inflammatory Response in Triple Negative Breast Cancer.#165611NCBI PubMed Central
• Astragaloside IV suppresses triple-negative breast cancer cell migration and invasion by targeting BCAT1-mediated branched-chain amino acid metabolism.#455258NCBI PubMed Central
• Discovery of ZJC-11 as a Novel Selective CDK7 Inhibitor for Treating Triple-Negative Breast Cancer by Inducing Cell Senescence.#472748NCBI PubMed Central
• The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.#966135ClinicalTrials.gov
• Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer#491985eScholarship
• A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors#910994ClinicalTrials.gov
• Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors#812228ClinicalTrials.gov
• Interpretable machine learning for prognostic prediction in young women with triple-negative invasive ductal breast cancer: a Boruta-SHAP integrated approach.#280920NCBI PubMed Central
• A bibliometric analysis of global research trends in adoptive cell therapy for triple negative breast cancer over the past 15 years.#281117NCBI PubMed Central
• TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.#320567NCBI PubMed Central
• Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysis.#362282NCBI PubMed Central
• MTUS2-AS1 suppression promotes DDX5 protein degradation to enhance the sensitivity of PARP inhibitors in BRCA-wild triple negative breast cancer.#412173NCBI PubMed Central
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)#861092ClinicalTrials.gov
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)#917956ClinicalTrials.gov
• Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative#830542ClinicalTrials.gov